DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7-Reference-Cited by-同舟云学术

DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7

Published:2016-09-01 Issue:9 Volume:128 Page:1214-1225
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Gkotzamanidou Maria¹²,Terpos Evangelos²,Bamia Christina³,Munshi Nikhil C.¹,Dimopoulos Meletios A.²,Souliotis Vassilis L.⁴

Affiliation:

1. Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;

2. Department of Clinical Therapeutics, and

3. Department of Hygiene, Epidemiology and Medical Statistics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece; and

4. Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, Athens, Greece

Abstract

Key Points Responders to melphalan therapy are characterized by slower rates of NER and DSB/R mechanisms and higher apoptotic rates. The DSB/R inhibitor SCR7 enhances cytotoxicity of melphalan against myeloma plasma cells.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/128/9/1214/1399286/1214.pdf

Reference53 articles.

1. Genetic events in the pathogenesis of multiple myeloma.;Chng;Best Pract Res Clin Haematol,2007

2. Pathogenesis of myeloma.;Anderson;Annu Rev Pathol,2011

3. 200 mg/m2 melphalan--the gold standard for multiple myeloma.;Giralt;Nat Rev Clin Oncol,2010

4. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.;Cavo;Blood,2011

5. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.;San Miguel;N Engl J Med,2008

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of a Novel Peptide-Based PET Tracer [⁶⁸Ga]Ga-DOTA-BP1 for BCMA Detection in Multiple Myeloma;Journal of Medicinal Chemistry;2024-08-21

2. The Interplay between the DNA Damage Response (DDR) Network and the Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in Multiple Myeloma;International Journal of Molecular Sciences;2024-06-26

3. Indisulam synergizes with melphalan to inhibit Multiple Myeloma malignancy via targeting TOP2A;PLOS ONE;2024-04-09

4. Selective inhibition of DNA ligase IV provides additional efficacy to the treatment of anaplastic thyroid cancer;Frontiers in Oncology;2024-02-06

5. Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft Models;Cancers;2023-08-21